AU2003272285A1 - Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands - Google Patents

Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands

Info

Publication number
AU2003272285A1
AU2003272285A1 AU2003272285A AU2003272285A AU2003272285A1 AU 2003272285 A1 AU2003272285 A1 AU 2003272285A1 AU 2003272285 A AU2003272285 A AU 2003272285A AU 2003272285 A AU2003272285 A AU 2003272285A AU 2003272285 A1 AU2003272285 A1 AU 2003272285A1
Authority
AU
Australia
Prior art keywords
furanopyrrolyl
thienopyrrolyl
histamine
compounds
receptor ligands
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003272285A
Other languages
English (en)
Other versions
AU2003272285A8 (en
Inventor
Hui Cai
Nicholas I. Carruthers
Curt A. Dvorak
James P. Edwards
Annette K. Kwok
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of AU2003272285A8 publication Critical patent/AU2003272285A8/xx
Publication of AU2003272285A1 publication Critical patent/AU2003272285A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2003272285A 2002-09-06 2003-09-05 Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands Abandoned AU2003272285A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40872302P 2002-09-06 2002-09-06
US60/408,723 2002-09-06
PCT/US2003/028017 WO2004022537A2 (en) 2002-09-06 2003-09-05 Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands

Publications (2)

Publication Number Publication Date
AU2003272285A8 AU2003272285A8 (en) 2004-03-29
AU2003272285A1 true AU2003272285A1 (en) 2004-03-29

Family

ID=31978666

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003272285A Abandoned AU2003272285A1 (en) 2002-09-06 2003-09-05 Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands

Country Status (12)

Country Link
US (3) US7226938B2 (enExample)
EP (1) EP1543011B1 (enExample)
JP (1) JP4596915B2 (enExample)
AT (1) ATE325125T1 (enExample)
AU (1) AU2003272285A1 (enExample)
CA (1) CA2497868C (enExample)
CY (1) CY1105080T1 (enExample)
DE (1) DE60305052T2 (enExample)
DK (1) DK1543011T3 (enExample)
ES (1) ES2264534T3 (enExample)
PT (1) PT1543011E (enExample)
WO (1) WO2004022537A2 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2264534T3 (es) * 2002-09-06 2007-01-01 Janssen Pharmaceutica N.V. Compuestos de tienopirrolilo y furanopirrolilo y su utilizacion como ligandos del receptor histaminico h4.
GB0222912D0 (en) * 2002-10-03 2002-11-13 Astrazeneca Ab Novel process and intermediates
GB0222909D0 (en) * 2002-10-03 2002-11-13 Astrazeneca Ab Novel process and intermediates
CA2540260A1 (en) * 2003-09-26 2005-04-07 Janssen Pharmaceutica N.V. Analyzing histamine h4 receptor-mediated effects in whole blood
AU2004312530A1 (en) * 2003-12-29 2005-07-21 Sepracor Inc. Pyrrole and pyrazole DAAO inhibitors
WO2005123673A1 (en) 2004-06-18 2005-12-29 Biolipox Ab Indoles useful in the treatment of inflammation
EP1776982A1 (en) * 2005-10-18 2007-04-25 Argenta Discovery Limited Pyrimidine compounds as histamine modulators
AU2005303893A1 (en) * 2004-11-11 2006-05-18 Argenta Discovery Ltd Pyrimidine compounds as histamine modulators
EP1671972A1 (en) * 2004-11-24 2006-06-21 Pfizer Limited Octahydropyrrolo[3,4-c]pyrrole derivatives
EP1846409A1 (en) * 2004-11-24 2007-10-24 Pfizer Limited Octahydropyrrolo[3,4-c]pyrrole derivatives
KR20070114123A (ko) 2005-01-19 2007-11-29 바이올리폭스 에이비 염증 치료에 유용한 인돌
WO2007006003A2 (en) 2005-07-06 2007-01-11 Sepracor Inc. Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
EP1767537A1 (en) * 2005-09-21 2007-03-28 Cellzome (UK) Ltd. Pyrimidine compounds for the treatment of inflammatory disorders
NL2000323C2 (nl) * 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.
KR101294014B1 (ko) 2006-01-06 2013-08-09 선오비온 파마슈티컬스 인코포레이티드 모노아민 재흡수 저해제로서의 시클로알킬아민
ES2566479T3 (es) * 2006-01-06 2016-04-13 Sunovion Pharmaceuticals Inc. Inhibidores de reabsorción de monoamina con base en tetralona
EP2816024B8 (en) 2006-03-31 2018-04-04 Sunovion Pharmaceuticals Inc. Chiral amines
ME01143B (me) 2006-03-31 2013-03-20 Janssen Pharmaceutica Nv BENZOIMIDAZOL-2-IL PIRIMIDINI l PIRAZINI KAO MODULATORI HISTAMINSKOG H4 RECEPTORA
US20090069343A1 (en) * 2006-04-10 2009-03-12 Dunford Paul J Combination Histamine H1R and H4R Antagonist Therapy for Treating Pruritus
US7884124B2 (en) 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
US20080058395A1 (en) * 2006-06-30 2008-03-06 Sepracor Inc. Fused heterocyclic inhibitors of D-amino acid oxidase
US7579370B2 (en) * 2006-06-30 2009-08-25 Sepracor Inc. Fused heterocycles
AU2007269646A1 (en) * 2006-06-30 2008-01-10 Sepracor Inc. Fused heterocyclic inhibitors of D-amino acid oxidase
US7985745B2 (en) 2006-10-02 2011-07-26 Abbott Laboratories Method for pain treatment
US20080082066A1 (en) * 2006-10-02 2008-04-03 Weyerhaeuser Co. Crosslinked carboxyalkyl cellulose fibers having non-permanent and temporary crosslinks
EP2298772A1 (en) 2006-10-18 2011-03-23 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
WO2008074445A1 (en) * 2006-12-18 2008-06-26 Ucb Pharma, S.A. Novel tricyclic and heterotricyclic derivatives, processes for preparing them, pharmaceutical compositions thereof
US7902252B2 (en) * 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
ZA200904686B (en) * 2007-01-18 2010-09-29 Sepracor Inc Inhibitiors of D-amino acid oxidase
CN101686672A (zh) 2007-05-31 2010-03-31 塞普拉柯公司 苯基取代的环烷胺作为一元胺再摄取抑制剂
NZ603074A (en) 2008-06-12 2013-08-30 Janssen Pharmaceutica Nv Use of histamine h4 antagonist for the treatment of post-operative adhesions
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
WO2010017418A1 (en) * 2008-08-07 2010-02-11 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
EP2201982A1 (en) 2008-12-24 2010-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Histamine H4 receptor antagonists for the treatment of vestibular disorders
EP2460794A4 (en) * 2009-07-31 2013-01-23 Shionogi & Co PHARMACEUTICAL COMPOSITION CONTAINING A CONDENSED HETEROCYCLIC DERIVATIVE
US20110034434A1 (en) * 2009-08-07 2011-02-10 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
EP3378476A1 (en) 2012-06-08 2018-09-26 Sensorion H4 receptor inhibitors for treating tinnitus
BR112015021463A8 (pt) 2013-03-06 2019-11-19 Janssen Pharmaceutica Nv moduladores de benzoimidazol-2-il pirimidina do receptor histamínico h4,seu uso e composição faramacêutica
TW201729810A (zh) 2015-10-26 2017-09-01 札爾科製藥公司 嘧啶組成物、其超純組成物及鹽類、製造彼之方法、及使用彼於治療組織胺h4受體(h 4 )仲介之疾病與病情之方法
CN109499595B (zh) * 2018-11-16 2021-10-08 中国林业科学研究院林产化学工业研究所 一种氧还原反应（orr）催化剂gpncs及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2571723B1 (fr) * 1984-10-12 1988-08-26 Lipha Derives de thieno et furo-(2,3-c) pyrroles, procedes de preparation et medicaments les contenant
NZ223654A (en) * 1987-03-09 1990-03-27 Janssen Pharmaceutica Nv 1-alkyl-substituted-benzimidazole-4-piperidinamines and pharmaceutical compositions
GB9803228D0 (en) 1998-02-17 1998-04-08 Zeneca Ltd Chemical compounds
DK1088824T3 (da) 1999-09-30 2004-04-13 Pfizer Prod Inc Bicykliske pyrrolylamider som glycogen phosphorylase inhibitorer
EP1136071A3 (en) 2000-03-22 2003-03-26 Pfizer Products Inc. Use of glycogen phosphorylase inhibitors
CA2440438C (en) 2001-03-09 2011-05-03 Ortho-Mcneil Pharmaceutical, Inc. Heterocyclic compounds
ES2264534T3 (es) * 2002-09-06 2007-01-01 Janssen Pharmaceutica N.V. Compuestos de tienopirrolilo y furanopirrolilo y su utilizacion como ligandos del receptor histaminico h4.

Also Published As

Publication number Publication date
DE60305052D1 (de) 2006-06-08
US7645758B2 (en) 2010-01-12
WO2004022537A3 (en) 2004-05-06
AU2003272285A8 (en) 2004-03-29
ATE325125T1 (de) 2006-06-15
DE60305052T2 (de) 2006-12-21
US7226938B2 (en) 2007-06-05
CY1105080T1 (el) 2009-11-04
US20070185131A1 (en) 2007-08-09
PT1543011E (pt) 2006-08-31
CA2497868A1 (en) 2004-03-18
DK1543011T3 (da) 2006-08-07
CA2497868C (en) 2010-11-30
WO2004022537A2 (en) 2004-03-18
EP1543011A2 (en) 2005-06-22
JP2006500394A (ja) 2006-01-05
ES2264534T3 (es) 2007-01-01
EP1543011B1 (en) 2006-05-03
US20040048878A1 (en) 2004-03-11
JP4596915B2 (ja) 2010-12-15
US20070185120A1 (en) 2007-08-09

Similar Documents

Publication Publication Date Title
AU2003272285A1 (en) Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands
BR0314059A (pt) Compostos heterocìclicos
WO2003094839A3 (en) Pyrimidinone compounds, compositions and methods
PL376440A1 (en) Pyridopyrrolizine and pyridoindolizine derivatives
WO2004018058A3 (en) Compounds, compositions, and methods
WO2003082208A8 (en) Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
TW200608979A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2003088903A3 (en) Compounds, compositions, and methods
MX2007002470A (es) Fenilaminotiazoles sustituidos y su uso.
WO2004009036A3 (en) Compounds compositions and methods
WO2005016883A3 (en) Acrylamide derivatives as vla-1 integrin antagonists and uses thereof
WO2003088748A8 (en) Use of heme oxygenase-1 and products of heme degradation
MXPA05004621A (es) Derivados de anilinopirazol utiles en el tratamiento de la diabetes.
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
WO2004034972A3 (en) Compounds, compositions, and methods
WO2004064741A3 (en) Compounds, compositions, and methods
NO20054371L (no) Somatostatin-dopamin kimaere analoger
WO2004006865A3 (en) Compounds, compositions, and methods
WO2004111047A3 (en) Cycloalkanepyrrolopyridines as dp receptor antagonists
WO2005046588A3 (en) Compounds, compositions, and methods
WO2004100873A3 (en) Compounds, compositions, and methods
WO2005042697A3 (en) Compounds, compositions and methods
WO2003092669A3 (en) Method of treating vascular endothelial growth factor mediated vascular disorders using amfenac or nepafenac
WO2005112923A3 (en) 5-anilino-4-heteroarylpyrazole derivatives useful for the treatment of diabetes
WO2004024086A3 (en) Compounds, compositions and methods

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase